CA2294141A1 - Nouvelle methode de traitement - Google Patents

Nouvelle methode de traitement Download PDF

Info

Publication number
CA2294141A1
CA2294141A1 CA002294141A CA2294141A CA2294141A1 CA 2294141 A1 CA2294141 A1 CA 2294141A1 CA 002294141 A CA002294141 A CA 002294141A CA 2294141 A CA2294141 A CA 2294141A CA 2294141 A1 CA2294141 A1 CA 2294141A1
Authority
CA
Canada
Prior art keywords
compound
administration
insulin
pharmaceutically acceptable
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002294141A
Other languages
English (en)
Inventor
Stephen Alistair Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2294141A1 publication Critical patent/CA2294141A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette méthode de traitement du diabète sucré et des états associés à celui-ci, chez un mammifère, consiste à administrer une dose efficace, non toxique et acceptable sur le plan pharmacologique du composé (I) et d'insuline à un mammifère nécessitant un tel traitement.
CA002294141A 1997-06-18 1998-06-15 Nouvelle methode de traitement Abandoned CA2294141A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GB9712866.4 1997-06-18
PCT/EP1998/003692 WO1998057636A1 (fr) 1997-06-18 1998-06-15 Nouvelle methode de traitement

Publications (1)

Publication Number Publication Date
CA2294141A1 true CA2294141A1 (fr) 1998-12-23

Family

ID=10814527

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002294141A Abandoned CA2294141A1 (fr) 1997-06-18 1998-06-15 Nouvelle methode de traitement

Country Status (30)

Country Link
EP (1) EP0999837A1 (fr)
JP (1) JP2002504138A (fr)
KR (1) KR20010013843A (fr)
CN (1) CN1133431C (fr)
AP (1) AP1287A (fr)
AR (2) AR012997A1 (fr)
AU (1) AU8216398A (fr)
BG (1) BG104059A (fr)
BR (1) BR9810444A (fr)
CA (1) CA2294141A1 (fr)
CO (1) CO4940454A1 (fr)
DZ (1) DZ2521A1 (fr)
EA (1) EA004800B1 (fr)
GB (1) GB9712866D0 (fr)
HU (1) HUP0003260A3 (fr)
ID (1) ID23951A (fr)
IL (1) IL133143A0 (fr)
IN (1) IN189723B (fr)
MA (1) MA26511A1 (fr)
NO (1) NO996265D0 (fr)
OA (1) OA11517A (fr)
PE (1) PE104499A1 (fr)
PL (1) PL343123A1 (fr)
SK (1) SK179399A3 (fr)
TR (1) TR199903095T2 (fr)
TW (1) TW587937B (fr)
UA (1) UA70299C2 (fr)
UY (1) UY25050A1 (fr)
WO (1) WO1998057636A1 (fr)
ZA (1) ZA985237B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
KR100744359B1 (ko) 1999-04-23 2007-07-30 스미스클라인비이참피이엘시이 티아졸리딘디온 유도체 및 항당뇨병제로서 그의 용도
EP1849475A1 (fr) 1999-06-21 2007-10-31 Eli Lilly & Company Utilisation synergique des thiazolidinediones avec peptide-1 comme glucagon et agonistes correspondants pour traiter les diabètes non dépendants de l'insuline
AU5760900A (en) 1999-06-25 2001-01-31 Minimed, Inc. Multiple agent diabetes therapy
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
WO2002067969A2 (fr) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Compositions d'insuline stabilisees
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
WO2002100396A1 (fr) * 2001-06-07 2002-12-19 Wyeth Combinaison d'un inhibiteur de la ptpase et d'un agent thiazolidinedione
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
CN1711084B (zh) * 2002-11-08 2010-04-28 霍夫曼-拉罗奇有限公司 作为ppar激动剂的取代4-烷氧基噁唑衍生物
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CN102389427A (zh) * 2011-10-10 2012-03-28 成都恒瑞制药有限公司 含有罗格列酮和盐酸西替利嗪的固体口服制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE376829T1 (de) * 1993-09-15 2007-11-15 Daiichi Sankyo Co Ltd Verwendung von thiazolidindionen zur vorbeugung oder verzögerung des auftretens des nichtinsulinabhängigen diabetes mellitus (niddm)
KR19990036290A (ko) * 1995-08-10 1999-05-25 로즈 암스트롱 비인슐린 의존성 진성 당뇨병 환자에 대한 외인성 인슐린 투여량의 감소 방법
EP0859608B1 (fr) * 1995-09-18 2004-02-11 Ligand Pharmaceuticals, Inc. Traitement de diabetes non insulino-dependants a l'aide d'agonistes de rxr

Also Published As

Publication number Publication date
IN189723B (fr) 2003-04-19
EP0999837A1 (fr) 2000-05-17
HUP0003260A2 (hu) 2001-05-28
IL133143A0 (en) 2001-03-19
NO996265L (no) 1999-12-17
UY25050A1 (es) 2000-09-29
AR015894A1 (es) 2001-05-30
EA200000042A1 (ru) 2000-08-28
AU8216398A (en) 1999-01-04
CN1133431C (zh) 2004-01-07
PL343123A1 (en) 2001-07-30
AR012997A1 (es) 2000-11-22
TR199903095T2 (xx) 2000-08-21
PE104499A1 (es) 2000-01-13
GB9712866D0 (en) 1997-08-20
CN1260715A (zh) 2000-07-19
BG104059A (en) 2000-10-31
SK179399A3 (en) 2000-11-07
BR9810444A (pt) 2000-09-05
EA004800B1 (ru) 2004-08-26
NO996265D0 (no) 1999-12-17
ZA985237B (en) 2000-02-17
OA11517A (en) 2004-02-04
MA26511A1 (fr) 2004-12-20
CO4940454A1 (es) 2000-07-24
HUP0003260A3 (en) 2001-12-28
UA70299C2 (en) 2004-10-15
KR20010013843A (ko) 2001-02-26
TW587937B (en) 2004-05-21
JP2002504138A (ja) 2002-02-05
ID23951A (id) 2000-06-08
AP9901718A0 (en) 1999-12-31
AP1287A (en) 2004-06-26
WO1998057636A1 (fr) 1998-12-23
DZ2521A1 (fr) 2003-02-08

Similar Documents

Publication Publication Date Title
EP0996444B1 (fr) Traitement du diabete a l'aide de thiazolidinedione et de metformine
US20030109553A1 (en) Treatment of diabetes with thiazolidinedione and metformin
AP1287A (en) Treatment of diabetes with rosiglitazone and insulin.
CA2292629C (fr) Composition renfermant de la 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
EP0999845B1 (fr) Traitement du diabete a l'aide de thiazolidinedione et de sulfonyluree
US20050054687A1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
US20040106543A1 (en) Treatment of diabetes with rosiglitazone and insulin
WO1999003478A1 (fr) Traitement du diabete avec du thiazolidinedione, un secretagogue d'insuline et un inhibiteur d'alpha glucosidase
CA2294134A1 (fr) Traitement du diabete a l'aide de thiazolidinedione et d'un inhibiteur des alpha-glucosidases
WO1999003476A1 (fr) Traitement du diabete avec du thiazolidinedione et de la sulfonyluree
AU783539B2 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
NZ518076A (en) 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (BRL49653) for treating non-insulin dependent diabetes (NIDDM)
AU1552102A (en) Treatment of diabetes with rosiglitazone and insulin
AU778947B2 (en) Treatment of diabetes with thiazolidinedione and metformin
US20030073645A1 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
MXPA99012065A (en) Treatment of diabetes with rosiglitazone and insulin
NZ520542A (en) Treatment of diabetes with thiazolidinedione and metformin

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued